Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CLDX
CLDX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CLDX News
CLDX Stock Price Fluctuation Analysis
Feb 05 2026
NASDAQ.COM
Celldex Therapeutics' Jimenez Sells 4,166 Shares for $121,210
Jan 12 2026
Fool
Celldex Offers $25 Put Option, Attracting Investor Interest
Dec 22 2025
NASDAQ.COM
Celldex Initiates Global Phase 3 Trial for Cold Urticaria Treatment
Dec 09 2025
Globenewswire
Celldex Initiates Global Phase 3 Trial for Barzolvolimab Efficacy in ColdU and SD
Dec 09 2025
Newsfilter
Cleveland Diagnostics' IsoPSA Receives FDA Approval, Enhancing Prostate Biopsy Decision-Making
Dec 01 2025
Businesswire
Tech Stocks Surge, Palantir Soars 6% as Shutdown Resolution Approaches: Market Movers for Monday
Nov 10 2025
Benzinga
Celldex Appoints Teri Lawver as Chief Commercial Officer
Nov 10 2025
Newsfilter
CLDX Options for December 2026 Now Available for Trading
Nov 07 2025
NASDAQ.COM
Mizuho Begins Coverage of Celldex Therapeutics, Assigns Outperform Rating and Sets Price Target at $48
Oct 21 2025
Benzinga
Analysts' Predictions for Celldex Therapeutics' Outlook
Oct 13 2025
Benzinga
Celldex Showcases Phase 2 Study Results at EADV Congress 2025 Indicating Barzolvolimab Enhances Chronic Spontaneous Urticaria Regardless of Initial Immunoglobulin E Levels
Sep 17 2025
Newsfilter
TMSL's Holdings Suggest a 14% Potential Increase
Aug 28 2025
NASDAQ.COM
Top Analysts Recommend 3 Best Stocks to Purchase Now, 8/25/2025
Aug 25 2025
TipRanks
Wells Fargo Keeps Overweight Rating on Celldex Therapeutics, Adjusts Price Target to $38
Aug 20 2025
Benzinga
Celldex Therapeutics Discontinues Investigational Drug for Eosinophilic Esophagitis Due to Inadequate Data
Aug 20 2025
Benzinga
Show More News
